paclitaxel and agar
paclitaxel has been researched along with agar in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bianco, AR; Caputo, R; Carlomagno, F; Ciardiello, F; Damiano, V; Fontanini, G; Tortora, G; Troiani, T; Veneziani, BM; Vitagliano, D | 1 |
| Anderson, E; Clarke, RB; Farnie, G; Howell, SJ; Hunter, T | 1 |
Other Studies
2 other study(ies) available for paclitaxel and agar
| Article | Year |
|---|---|
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Topics: Agar; Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Paclitaxel; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.
Topics: Agar; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; DNA, Complementary; Doxorubicin; Humans; Immunohistochemistry; Paclitaxel; Prolactin; Receptors, Prolactin; Reverse Transcriptase Polymerase Chain Reaction; Rhodamines; RNA, Messenger | 2008 |